Skip to content

US · HQL · ASSET MANAGEMENT

Tekla Life Sciences Investors (HQL) intrinsic value and stock valuation

$15.38as of 2026-11-21 · Mkt cap 605.12M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tekla Life Sciences Investors DCF and intrinsic value

InvestorsCraft values HQL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from HQL’s statements →

Tekla Life Sciences Investors Graham Number

Graham Number: $34.45d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Financial Services · Asset Management Philadelphia, PA 19103 aberdeeninvestments.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$86.4M+17.2% 5y CAGRd
20112025
Net income
$85.6M-7% 5y CAGRd
20112025
Free cash flow
-$-2.32M
20102025
Total equity
$513.7M+1.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$86.4M$86.7M$39.4M$31.9M$45M
Operating income$85.6M$85.3M-$-5.24M-$-104.6M$64.5M
Net income$85.6M$85.3M$22.4M-$-104.6M$64.5M
EPSd$2.96M$3.04M$790K-$-4.07M$2.66M
Operating cash flow-$-2.32M—$0.00$0.00$0.00
Capital expenditure-$0.00—$0.00$0.00$0.00
Free cash flow-$-2.32M—$0.00$0.00$0.00
Total assets$515.4M$460.6M$402.6M$414.7M$534.2M
Total debt$0.00$0.00$0.00$11.1M$1.34M
Net debt-$-80K-$0.00-$0.00$10K$1.34M
Total equity$513.7M$459.7M$401.9M$397.9M$523.4M
Cash and short-term investments$80K$0.00$15.2M$0.00$0.00
Income statement
20252024202320222021
Revenue$86.4M$86.7M$39.4M$31.9M$45M
Cost of revenue$4.97M$5.36M$5.24M$5.55M$6.08M
Gross profit$86.4M$86.7M$18.3M$26.3M$39M
Research and development expenses$0.00$0.00$0.00-$0.00$0.00
Selling, general and administrative expenses$740K$1.33M$900K$1.08M$840K
Other expenses$50K$60K$270K$280K$310K
Operating expenses$790K$1.39M$1.17M$1.35M$1.16M
Cost and expenses$790K$1.39M$17M$136.5M-$-19.51M
Interest income$350K$1.04M$200K$50K$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$1.92M$27.6M$2.99M$4.14M
Ebitda$85.6M$87.2M$50M-$-101.62M$68.7M
Operating income$85.6M$85.3M-$-5.24M-$-104.6M$64.5M
Total other income/expenses, net$0.00$87.2M$27.6M$0.00-$-10K
Income before tax$85.6M$85.3M$22.4M-$-104.6M$64.5M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income$85.6M$85.3M$22.4M-$-104.6M$64.5M
Weighted average shares outstanding$28.9M$28.1M$28.3M$25.7M$24.3M
Weighted average diluted shares outstanding$28.9M$28.1M$28.3M$25.7M$24.3M
Balance sheet
20252024202320222021
Cash and short-term investments$80K$0.00$15.2M$0.00$0.00
Net receivables$1.14M$230K$5.04M$620K$150K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$1.25M$280K$5.05M$620K$140K
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$505.7M$460.3M$397.5M$414.1M$534M
Total non-current assets$514.1M$474.2M$397.5M$414.1M$534M
Total assets$515.4M$460.6M$402.6M$414.7M$534.2M
Accounts payable$720K$0.00$0.00$5.1M$150K
Short-term debt$0.00$0.00$0.00$11.1M$10M
Deferred revenue$0.00$0.00$0.00$5.09M$0.00
Total current liabilities$720K$890K$0.00$5.1M$10.8M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.01M$890K$670K$11.7M$10.8M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$1.73M$890K$670K$16.8M$10.8M
Common stock$300K$280K$270K$260K$250K
Retained earnings$77.6M$44.1M-$-1.48M$9.55M$150.7M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$513.7M$459.7M$401.9M$397.9M$523.4M
Total investments$514.1M$477.5M$412.8M$414.1M$534M
Total debt$0.00$0.00$0.00$11.1M$1.34M
Net debt-$-80K-$0.00-$0.00$10K$1.34M
Cash flow statement
20252023202220212020
Net income$85.6M$22.4M-$-100K$60K$120K
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-200K$0.00$0.00$0.00$0.00
Accounts receivable$60K$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-2.32M$0.00$0.00$0.00$0.00
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$25.2M$0.00$0.00$0.00$0.00
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-31.63M$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-31.63M$0.00$0.00$0.00$0.00
Net change in cash$80K$0.00-$0.00$0.00$0.00
Cash at end of period$80K$0.00$0.00$0.00$1.12M
Operating cash flow-$-2.32M$0.00$0.00$0.00$0.00
Capital expenditure-$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-2.32M$0.00$0.00$0.00$0.00
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tekla Life Sciences Investors

        Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.

        CEO
        Daniel R. Omstead
        Employees
        0
        Beta
        0.71

        Explore

        Frequently asked questions

        What is the intrinsic value of Tekla Life Sciences Investors (HQL)?

        InvestorsCraft does not currently publish an intrinsic value for HQL. How the IC value is calculated.

        Is HQL undervalued?

        InvestorsCraft does not publish an undervaluation signal for HQL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.